Raleigh Capital Management Inc. Alkermes Plc. Transaction History

Raleigh Capital Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 21, 2024	BUY	$23.37 - $28.68 $373 - $458	16 Added 4.68%	358 $9,000
Q3 2023 Dec 06, 2023	BUY	$27.17 - $31.97 $896 - $1,055	33 Added 10.68%	342 $9,000
Q2 2023 Jul 25, 2023	BUY	$28.34 - $33.63 $3,315 - $3,934	117 Added 60.94%	309 $9,000
Q1 2023 May 22, 2023	BUY	$25.31 - $29.02 $936 - $1,073	37 Added 23.87%	192 $5,000
Q4 2022 Feb 07, 2023	BUY	$21.94 - $26.24 $1,491 - $1,784	68 Added 78.16%	155 $4,000
Q3 2022 Nov 09, 2022	BUY	$22.0 - $31.87 $1,914 - $2,772	87 New	87 $2,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Raleigh Capital Management Inc. with notifications on news.